{"id":"NCT03917472","sponsor":"Novartis Pharmaceuticals","briefTitle":"Efficacy and Safety of Brolucizumab vs Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema","officialTitle":"A 12-Month, 2-Arm, Randomized, Double-Masked, Multicenter Phase III Study Assessing the Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema (KINGFISHER)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-07-17","primaryCompletion":"2021-03-24","completion":"2021-03-24","firstPosted":"2019-04-17","resultsPosted":"2022-04-21","lastUpdate":"2022-08-12"},"enrollment":517,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetic Macular Edema"],"interventions":[{"type":"DRUG","name":"Brolucizumab","otherNames":["RTH258, ESBA1008"]},{"type":"DRUG","name":"Aflibercept","otherNames":["Eylea"]}],"arms":[{"label":"Brolucizumab 6mg q4w","type":"EXPERIMENTAL"},{"label":"Aflibercept 2mg q4w","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study was to evaluate the efficacy and safety of brolucizumab vs. aflibercept in the treatment of patients with visual impairment due to diabetic macular edema (DME).","primaryOutcome":{"measure":"Change From Baseline in Best-corrected Visual Acuity (BCVA) at Week 52","timeFrame":"Baseline, Week 52","effectByArm":[{"arm":"Brolucizumab 6mg q4w","deltaMin":12.2,"sd":null},{"arm":"Aflibercept 2mg q4w","deltaMin":11,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.099"},{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":8},"locations":{"siteCount":92,"countries":["United States","Hungary","Israel","Puerto Rico","Slovakia"]},"refs":{"pmids":["37971723"],"seeAlso":["https://www.novctrd.com/ctrdweb/patientsummary/patientsummaries?patientSummaryId=1085"]},"adverseEventsSummary":{"seriousAny":{"events":74,"n":346},"commonTop":["Hypertension","COVID-19","Diabetic retinal oedema - Fellow eye","Vitreous detachment - Study eye","Conjunctival haemorrhage - Study eye"]}}